Multiple Sclerosis Journal

Article	Citations
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	123
Sars-CoV2 infection in pregnant women with multiple sclerosis	92
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	89
Time to move past typical syndromes in the diagnosis of multiple sclerosis	74
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	63
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	61
Therapy challenges for NMOSD in a patient with HIV	55
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	54
Impact of cancer on multiple sclerosis–related healthcare and disease-modifying drug use: A multinational cohort study	51
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder	50
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088.	48
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab	46
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial	42
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities	42
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	40
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	39
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab	38
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	37
Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study	37
Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab	36
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	35
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	34
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	34
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	34
Double-negative neuromyelitis optica spectrum disorder	32

Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage	32
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis	32
Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack	31
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study	31
High-risk populations should be screened for MS—Commentary	31
White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study	30
Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation	30
Anti-CD20 therapy in pregnancy: Balancing risks and benefits	29
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics	29
Pseudocystic demyelination in multiple sclerosis	28
Aspergillus myelitis : Breaking the mold to make a diagnosis	28
To halt disease progression rehabilitation in MS should start early: Yes	27
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	27
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis	26
Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients	26
Biological aging in multiple sclerosis	26
Immunosenescence in multiple sclerosis: New insights and clinical implications	26
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022	25
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis	25
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society	24
Preventing frailty in multiple sclerosis is a realistic goal – No	24
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry	24
Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis	23
Metabolic and lipid alterations in multiple sclerosis linked to disease severity	22
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial	22
Optic nerve assessments in MS diagnosis are worth the added implementation complexity: Yes	22
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study	22
Low transfer of cladribine into human milk	22
Ofatumumab-associated colitis: A case report	21
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor	21
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community	21
Depression is a core symptom of multiple sclerosis: Yes	21
Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model	21
The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study	21
What is a clinically isolated syndrome in the 21st century?	21
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis	21
Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model	21
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort	21
Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort	20
High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate	20
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis	20
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis	20
ECTRIMS 2024 Lecture: Unraveling the spectrum of the antibody-mediated demyelinating diseases: Emerging insights	19
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France	19
Filtered-phase imaging versus susceptibility-weighted imaging for paramagnetic rim lesion detection in multiple sclerosis: A head-to-head comparison	19
Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder	19
Are neurofilament light chain levels ready for routine clinical use? – Commentary	19
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis	19
Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis	19
Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No	19

Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration	18
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis	18
The revised 2024 McDonald criteria can solve the misdiagnosis problem in multiple sclerosis: Commentary	18
Mobile health interventions in multiple sclerosis: A systematic review	18
The MoXFo initiative – adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research	18
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis	18
Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome	18
Novel MRI metrics: Is targeting brain atrophy a practical treatment goal? Yes	17
Navigating the uncharted—Progressive multifocal leukoencephalopathy in a child with NMOSD treated with rituximab	17
Telomere length as a biomarker in multiple sclerosis	17
ACTRIMS Forum 2026 - Author Index	17
Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals	17
Baló’s concentric sclerosis successfully treated with alemtuzumab: Long-term follow-up	16
Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021	16
Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis	16
Exercise as a Therapeutic Intervention in Multiple Sclerosis	16
New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series	16
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort	16
Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach	16
Towards a phenotypic understanding of multiple sclerosis depression	15
Addressing me in the context of my disease: Why it is so complicated	15
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study	15
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis	15
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations	15
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort stu	15
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement	15
Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis	14
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model	14
Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden	14
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy	14
Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort	14
Machine learning classification of multiple sclerosis in children using optical coherence tomography	14
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis	14
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	14
Exosomal profiling should be used to monitor disease activity in MS patients: Commentary	13
Response to letter to the editor “Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs”	13
Response to letter to the editor: ‘Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis’	13
Cognitive reserve in multiple sclerosis: The role of depression and fatigue	13
ACTRIMS Forum 2023 Invited Program	13
Characteristics of multiple sclerosis and demyelinating disease in an Asian American population	13
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO	13
The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS	13
Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort	13
External validation of a clinical prediction model in multiple sclerosis	13
A taxonomic approach to cognitive diagnostics is viable and achievable in MS	13
ACTRIMS Forum 2025 Author Index	13
Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis	13
Assessing the association between mortality and clinical follow-up visits in multiple sclerosis	13
All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes	13
Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study	12
Acute retinal necrosis associated with dimethyl fumarate	12
ACTRIMS Forum 2023 - Poster Presentations	12
From “invisible” to “audible”: Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis	12
Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States	12
Spinal cord imaging in multiple sclerosis: A vital component we can no longer overlook	12
Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis	12
Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada	12
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice	12
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clini	12
The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives	12
ECTRIMS 2024 – Oral Presentations	12
Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics - Yes	12
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis	12
Prevalence of neuromyelitis optica spectrum disorder in the United States	12
Differential vulnerability of thalamic nuclei in multiple sclerosis	12
Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors	12
AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research	12
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study	12
Choroid plexus enlargement correlates with demyelinating lesions and thalamic atrophy in radiologically isolated syndrome	11
MS becomes a treatable disease: 30 years later	11
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data	11
Homonymous hemi-macular atrophy in multiple sclerosis	11
Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder	11
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study	11
Toward a global research agenda for preventing multiple sclerosis	11
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC)	11
Unveiling Misdiagnosis: Rethinking Seronegative NMOSD	11
Association between education level and disability progression in patients with multiple sclerosis in France	11
Neurofilament light biomarkers in MS: Effects of extended natalizumab dosing	11
Clinical commentary to “the cascade sign in aquaporin-4-IgG positive (AQP4-IgG+) NMOSD”	11

Exosomal profiling should be used to monitor disease activity in MS patients: No	11
The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis	11
The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research	11
Persistent gadolinium enhancement: An emerging MRI feature in NMOSD?	11
ACTRIMS Forum 2023 Author Index	10
Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome	10
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study	10
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease	10
Depression is a core symptom of multiple sclerosis: No	10
Anaphylaxis and glatiramer acetate	10
Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter	10
Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis	10
Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains	10
Influence of OSCAR-IB criteria on test–retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis	10
Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study	10
Relapsing tumefactive demyelination: time to recognize a distinct demyelinating condition?	10
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography	10
Early corticosteroids predict visual whereas MRI lesion extent predicts retinal atrophy outcomes in MOG antibody–associated optic neuritis	10
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial	10
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial	10
T1-based stratification of paramagnetic rim lesions in multiple sclerosis: Evidence of microstructural heterogeneity and clinical implications	10
Treating comorbidities in multiple sclerosis is disease modifying: Yes	10
Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient	10
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	10
Seizure history and cognitive dysfunction in people with multiple sclerosis	10
Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study	9
Dysarthria assessment in multiple sclerosis patients	9
Unemployment, work hour reduction, and income loss: An international, multicentered, cross-sectional study of neuromyelitis optica spectrum disorder	9
Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease	9
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	9
Racial identity, marginalization, and depression in pediatric-onset multiple sclerosis	9
Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study	9
Generic MS medications: Reducing costs without compromising safety	9
Event-related potentials and behavioural correlates of cognitive functions in MS: An EEG study during symbol digit modalities test	9
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study	9
Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status	9
UK consensus on pregnancy in multiple sclerosis: An update to ‘Association of British Neurologists’ guidance	9
Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty	9
Treating comorbidities in MS is disease modifying: Commentary	9
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients	9
Facial pain in MS: When to think of trigeminal autonomic cephalalgia	9
Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis	9
Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial	9
Employment status, productivity loss, and associated factors among people with multiple sclerosis	9
Quantifying observable movement reserve in multiple sclerosis via upper diurnal activity quantiles	9
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS	9
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis	8
A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial	8
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis	8
Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study	8
Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis	8
Committees	8
Genetic mimics of neuromyelitis optica spectrum disorder	8
Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Commentary	8
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse	8
Should autologous HSCT be a first-line option in highly active MS? No	8
How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder	8
Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs	8
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas	8
Abstracts presented at the 10th Annual Meeting International MS Cognition Society (IMSCOGS), 2-3 September 2024, Bern, Switzerland	8
Multiple sclerosis can be diagnosed solely with dissemination in space: Yes	8
Rectifying global inequities in neuromyelitis optica diagnosis and treatment	8
Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure	8
Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?	8
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Dis	8
ACTRIMS Forum 2026 - Poster Presentations	8
Trends in central nervous system-active polypharmacy among people with multiple sclerosis	8
Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis	8
Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders	8
Causal effects of multiple sclerosis therapies in left-truncated registry data	8
The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now	8
Cladribine: A useful treatment option in multiple sclerosis patients with autoimmune comorbidities	8
Toward a holistic approach to multiple sclerosis: The role of social determinants of health	8
The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study	8
Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials	7
Commentary on: Acute retinal necrosis associated with dimethyl fumarate	7
The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review	7
Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod	7
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study	7
Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis	7
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension t	7
Imaging the Choroid Plexus	7
Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system	7
Artificial intelligence will change MS care within the next 10 years: Commentary	7
Enhancing diversity of clinical trial populations in multiple sclerosis	7
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)	7
Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study	7
Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis	7
Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination	7
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark	7
Tumefactive demyelinating lesion during B-cell depletion therapy by ofatumumab	7
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discont	7
Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs	7
Choroid plexus volume differentiates MS from its mimics	7
Therapeutic lag: Is treatment effect delayed in progressive MS?	7